Search results
Click a Field or Translation tag to filter the publications. Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics. Pharmacol Ther. 2023 02; 242:108337. Stehle D, Barresi M, Schulz J, Feil R. PMID: 36623589.
- 9500 Gilman Drive # La Jolla CA 92093
- Vc-health Sciences-schools
- Postdoctoral Scholar, Pharmacology
- Postdoctoral Scholar, Pharmacology
We are happy and proud that one of our IFIB junior scientists, Daniel Stehle (Feil Lab), has received this year's PhD award from the University of Tübingen. His PhD thesis is entitled “cGMP Imaging Uncovers New Roles and Therapeutic Implications of NO/cGMP Signaling in the Kidney and in Melanoma”.
Daniel Stehle's 11 research works with 127 citations and 788 reads, including: Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer...
View Daniel Stehle’s profile on LinkedIn, a professional community of 1 billion members.
- 229
- UC San Diego
- 237
- San Diego, California, United States
Jul 3, 2021 · Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem‐free form, apo‐sGC. Apo‐sGC cannot be activated by NO, resulting in impaired cGMP signalling that is associated with chronic kidney disease progression.
- 10.1111/bph.15586
- 2022/06
- Br J Pharmacol. 2022 Jun; 179(11): 2476-2489.
Dec 11, 2019 · View Daniel Trevijano Stehle’s profile on LinkedIn, a professional community of 1 billion members. I studied architecture at the University of Navarra in Spain and have collaborated over… ·...
- Fletcher Priest Architects
Semantic Scholar profile for Daniel Stehle, with 4 highly influential citations and 12 scientific research papers.
